^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:rezivertinib (BPI-7711) (EGFR antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    BMC Med
    Title:

    Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

    Published date:
    01/08/2023
    Excerpt:
    Rezivertinib (BPI-7711) showed promising efficacy and a favorable safety profile for the treatment among the locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation in the first-line setting.
    DOI:
    https://doi.org/10.1186/s12916-022-02692-8
    Trial ID:
    NCT03386955
    Test:
    cobas® EGFR Mutation Test v2
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2022
    Title:

    981P - A phase IIa study to evaluate safety and efficacy of rezivertinib (BPI-7711) in locally advanced or metastatic/recurrent treatment-naïve NSCLC patients with EGFR mutation

    Published date:
    09/05/2022
    Excerpt:
    This study aimed to evaluate the efficacy and safety of rezivertinib in treatment-naïve patients with locally advanced or metastatic/recurrent EGFR mutated non-small cell lung cancer (NSCLC)....Rezivertinib showed promising efficacy and favorable safety for locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation at first-line setting.
    Trial ID:
    NCT03386955